Webinar Date and Time: Wednesday, November 9, 2022 4:00 – 5:00 pm EST
As the first webinar in the Novel Lymphoma Therapies series, Dr. Michael Rauh and two of his trainees will provide an overview of precision-based medicine & research. This presentation will define what personalized medicine is, and how research can help doctors choose treatment options based on an individual’s genetic and molecular profile of cancer. This talk will highlight how precision-based medicine & research can help lymphoma patients access treatment options in Canada.
Speakers: Dr. Michael Rauh, Dr. Gillian Kupakuwana-Suk, Mr. Marco Buttigieg
Dr. Michael Rauh
Dr. Michael Rauh is a staff hematopathologist at the Kingston General Hospital and an Assistant Professor in the department of Pathology & Molecular Medicine at Queen’s University. He leads a research group that studies genetic and immune pathogenesis of myeloid cancer. Dr. Rauh and his students are dedicated to discovering novel biomarkers and treatment targets, supporting personalized diagnosis and care for those diagnosed with hematological malignancies.
Dr. Gillian Kupakuwana-Suk
Gillian Kupakuwana-Suk is a 4th year hematology resident at Queen’s University and recently joined Dr. Rauh’s lab with a focus on clonal hematopoiesis in Lymphoma. She attended medical school at Columbia University in New York and completed her internal medicine training at Yale and has a keen interest in understanding mutational evolution leading up to hematologic malignancies.
Mr. Marco Buttigieg
Marco is a 4th year undergraduate student in the Bachelor of Health Sciences program at Queen’s University. He is currently completing his thesis project in Dr. Rauh’s lab studying how clonal hematopoiesis can influence cancer progression and metastasis and will be continuing with his studies in the lab next year for his master’s degree. He is from Toronto, Ontario.